We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Santen Pharmaceutical Company (PK) | USOTC:SNPHY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.9455 | -7.76% | 11.233 | 10.14 | 12.55 | 11.33 | 11.233 | 11.325 | 437 | 22:00:01 |
From Dec 2019 to Dec 2024
By Matt Grossman
Aerie Pharmaceuticals Inc. has completed patient enrollment of a Phase 3 study in Japan testing its netarsudil ophthalmic solution as a treatment for glaucoma or ocular hypertension, Aerie said Thursday.
The Durham, N.C.-based pharmaceutical company said that the study has enrolled 245 patients. The patients have received treatment either with netarsudil or with ripasudil, another solution that is approved in Japan. The trial is expected to be completed by the end of 2021, Aerie said.
Netarsudil has already been approved to treat some eye conditions in the U.S. The Japanese study is being co-funded with Santen Pharmaceutical Co., which has an exclusive collaboration and license agreement with Aerie for netarsudil in Japan and other Asian countries.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
June 17, 2021 06:55 ET (10:55 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Santen Pharmaceutical (PK) Chart |
1 Month Santen Pharmaceutical (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
